|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 植物表型组学:发展、现状与挑战显示文摘随着遥感、机器人技术、计算机视觉和人工智能的发展,植物表型组学研究已经步入了快速成长阶段。本文首先介绍了植物表型组学的发展简史,包括其理论核心、研究方法、在生物研究中的应用以及国际上最新的研究动向。然后,针对各类表型技术载体平台如手持、人载、车载、田间实时监控、大型室内外自动化平台和航空机载等,分析这些技术手段在室内、外植物研究中的应用情况和实际问题。为了对表型研究中产生的巨量图像和传感器数据进行量化分析,把大数据转化为有实际意义的性状信息和生物学知识,本文着重讨论了后期表型数据解析和相应的研发过程。最后,提出表型组学的应用前景与未来展望,以期为中国的表型研究提供指导和建议。 | 周济 Francois Tardieu Tony Pridmore John Doonan Daniel Reynolds Neil Hall Simon Griffiths 程涛 朱艳 王秀娥 姜东 丁艳锋 | 2018 | 南京农业大学学报2018，41，4： | 64 |
| 2 | Non-antibiotic feed additives in diets for pigs:A review显示文摘A number of feed additives are marketed to assist in boosting the pigs' immune system, regulate gut microbiota, and reduce negative impacts of weaning and other environmental challenges.The most commonly used feed additives include acidifiers, zinc and copper, prebiotics, direct-fed microbials, yeast products, nucleotides, and plant extracts.Inclusion of pharmacological levels of zinc and copper, certain acidifiers, and several plant extracts have been reported to result in improved pig performance or improved immune function of pigs.It is also possible that use of prebiotics, direct-fed microbials, yeast,and nucleotides may have positive impacts on pig performance, but results have been less consistent and there is a need for more research in this area. | Yanhong Liu Charmaine D.Espinosa Jerubella J.Abelilla Gloria A.Casas L.Vanessa Lagos Su A.Lee Woong B.Kwon John K.Mathai Diego M.D.L.Navarro Neil W.Jaworski Hans H.Stein | 2018 | Animal Nutrition2018，，2： | 41 |
| 3 | Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly?显示文摘ObjectiveTo evaluate 心脏的同一时刻治疗(CRT ) 培植是否与经历 CRT 培植的 symptoms.MethodsConsecutive 病人一起在 octogenarians 和协会可行、安全,从二个英国中心被招募。根据年龄组织的病人:<80 &≥80 年。基线人口分布,复杂并发症和结果在 439 个病人的那些 groups.ResultsA 总数之间被比较在这研究, 26%≥ 是谁被包括;80 年。Octogenarians 更经常与心脏的同一时刻治疗使用高压脉冲来消减心脏相比收到了心脏的再同步治疗心律调整器。从心律调整器的升级在两个组是普通的(16%<80 年对 22%≥80 年, P = NS ) 。合作病态在两个组是同样普通的(全面糖尿病:25% , atrial 纤维性颤动:23% ,高血压:45%) 。更耐心的年龄 ≥80 年有重要的长期的肾疾病(CKD,估计的 glomerular 过滤率 <45 mL/min 每 1.73 m 2,44% 对 22% , P <0.01 ) 。全面复杂并发症率(任何东西) 在两个组是类似的(16% 对 17% , P = NS ) 。两个组表明了征兆的利益。一个年死亡率作为与更年轻的队相比是在 octogenarians 更大的几乎四褶层(13.9% 对 3.7% , P <0.01 ).ConclusionsCRT 看起来安全在尽管有广泛的合作病态老、特别地经常严重 CKD。征兆的改进看起来有意义。增加的策略是 CRT 的潜在的候选人的有 CHF 的老病人的适当鉴定被要求。 | Bartosz Olechowski Rebecca Sands Donah Zachariah Neil P Andrews Richard Balasubramaniam Mark Sopher John Paisey Paul R Kalra | 2015 | Journal of Geriatric Cardiology2015，12，5： | 5 |
| 4 | Mediastinal node staging by positron emission tomographycomputed tomography and selective endoscopic ultrasound with fine needle aspiration for patients with upper gastrointestinal cancer:Results from a regional centre显示文摘AIM To investigate the impact of endoscopic ultrasound-guided fine-needle aspiration(EUS-FNA) and positron emission tomography-computed tomography(PET-CT) in the nodal staging of upper gastrointestinal(GI) cancer in a tertiary referral centre.METHODS We performed a retrospective review of prospectively recorded data held on all patients with a diagnosis of upper GI cancer made between January 2009 and December 2015. Only those patients who had both a PET-CT and EUS with FNA sampling of a mediastinal node distant from the primary tumour were included. Using a positive EUS-FNA result as the gold standard for lymph node involvement, the sensitivity, specificity, positive and negative predictive values(PPV and NPV) and accuracy of PET-CT in the staging of mediastinal lymph nodes were calculated. The impact on therapeutic strategy of adding EUS-FNA to PET-CT was assessed.RESULTS One hundred and twenty one patients were included. Sixty nine patients had a diagnosis of oesophageal adenocarcinoma(Thirty one of whom were junctional), forty eight had oesophageal squamous cell carcinoma and four had gastric adenocarcinoma. The FNA results were inadequate in eleven cases and the PET-CT findings were indeterminate in two cases, therefore thirteen patients(10.7%) were excluded from further analysis. There was concordance between PET-CT and EUS-FNA findings in seventy one of the remaining one hundred and eight patients(65.7%). The sensitivity, specificity, PPV and NPV values of PET-CT were 92.5%, 50%, 52.1% and 91.9% respectively. There was discordance between PET-CT and EUS-FNA findings in thirty seven out of one hundred and eight patients(34.3%). MDT discussion led to a radical treatment pathway in twenty seven of these cases, after the final tumour stage was altered as a direct consequence of the EUS-FNA findings. Of these patients, fourteen(51.9%) experienced clinical remission of a median of nine months(range three to forty two months). CONCLUSION EUS-FNA leads to altered staging of upper GI cancer, resulting in more patients receiving radical treatment that would have been the case using PET-CT staging alone. | Chris Harrington Lyn Smith Jennifer Bisland Elisabet López González Neil Jamieson Stuart Paterson Adrian John Stanley | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，1： | 4 |
| 5 | Ampullary cancer of intestinal origin and duodenal cancer-A logical clinical and therapeutic subgroup in periampullary cancer显示文摘Periampullary cancers include pancreatic, ampullary, biliary and duodenal cancers. At presentation, the majority of periampullary tumours have grown to involve the pancreas, bile duct, ampulla and duodenum. This can result in difficulty in defining the primary site of origin in all but the smallest tumors due to anatomical proximity and architectural distortion. This has led to variation in the reported proportions of resected periampullary cancers. Pancreatic cancer is the most common cancer resected with a pancreaticoduodenectomy followed by ampullary(16%-50%), bile duct(5%-39%), and duodenal cancer(3%-17%). Patients with resected duodenal and ampullary cancers have a better reported median survival(29-47 mo and 22-54 mo) compared to pancreatic cancer(13-19 mo). The poorer survival with pancreatic cancer relates to differences in tumour characteristics such as a higher incidence of nodal, neural and vascular invasion. While small ampullary cancers can present early with biliary obstruction, pancreatic cancers need to reach a certain size before biliary obstruction ensues. This larger size at presentation contributes to a higher incidence of resection margin involvement in pancreatic cancer. Ampullary cancers can be subdivided into intestinal or pancreatobiliary subtype cancers with histomolecular staining. This avoids relying on histomorphology alone, as even some poorly differentiated cancers preserve the histomolecular profile of their mucosa of origin. Histomolecular profiling is superior to anatomic location in prognosticating survival. Ampullary cancers of intestinal subtype and duodenal cancers are similar in their intestinal origin and form a logical clinical and therapeutic subgroup of periampullary cancers. They respond to 5-FU based chemotherapeutic regimens such as capecitabine-oxaliplatin. Unlike pancreatic cancers, KRAS mutation occurs in only approximately a third of ampullary and duodenal cancers. Future clinical trials should group ampullary cancers of intestinal origin and duodenal cancers together given their similarities and their response to fluoropyrimidine therapy in combination with oxaliplatin. The addition of anti-epidermal growth factor receptor therapy in this group warrants study. | Manju D Chandrasegaram Anthony J Gill Jas Samra Tim Price John Chen Jonathan Fawcett Neil D Merrett | 2017 | World Journal of Gastrointestinal Oncology2017，9，10： | 4 |
| 6 | Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma显示文摘Although genome-wide association studies have identified more than eighty genetic variants associated with non-small cell lung cancer(NSCLC)risk,biological mechanisms of these variants remain largely unknown.By integrating a large-scale genotype data of 15581 lung adenocarcinoma(AD)cases,8350 squamous cell carcinoma(SqCC)cases,and 27355 controls,as well as multiple transcriptome and epigenomic databases,we conducted histology-specific meta-analyses and functional annotations of both reported and novel susceptibility variants.We identified 3064 credible risk variants for NSCLC,which were overrepresented in enhancer-like and promoter-like histone modification peaks as well as DNase I hypersensitive sites.Transcription factor enrichment analysis revealed that USF1 was AD-specific while CREB1 was SqCC-specific.Functional annotation and genebased analysis implicated 894 target genes,including 274 specifics for AD and 123 for SqCC,which were overrepresented in somatic driver genes(ER=1.95,P=0.005).Pathway enrichment analysis and Gene-Set Enrichment Analysis revealed that AD genes were primarily involved in immune-related pathways,while SqCC genes were homologous recombination deficiency related.Our results illustrate the molecular basis of both wellstudied and new susceptibility loci of NSCLC,providing not only novel insights into the genetic heterogeneity between AD and SqCC but also a set of plausible gene targets for post-GWAS functional experiments. | Na Qin Yuancheng Li Cheng Wang Meng Zhu Juncheng Dai Tongtong Hong Demetrius Albanes Stephen Lam Adonina Tardon Chu Chen Gary Goodman Stig EBojesen Maria Teresa Landi Mattias Johansson Angela Risch H-Erich Wichmann Heike Bickeboller Gadi Rennert Susanne Arnold Paul Brennan John KField Sanjay Shete Loic Le Marchand Olle Melander Hans Brunnstrom Geoffrey Liu Rayjean JHung Angeline Andrew Lambertus AKiemeney Shan Zienolddiny Kjell Grankvist Mikael Johansson Neil Caporaso Penella Woll Philip Lazarus Matthew BSchabath Melinda CAldrich Victoria LStevens Guangfu Jin David CChristiani Zhibin Hu Christopher IAmos Hongxia Ma Hongbing Shen | 2021 | Frontiers of Medicine2021，15，2： | 3 |
| 7 | Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension显示文摘Myeloid cells,such as neutrophils,are produced in the bone marrow in high quantities and are important in the pathogenesis of vascular diseases such as pulmonary hypertension(PH).Although neutrophil recruitment into sites of inflammation has been well studied,the mechanisms of neutrophil egress from the bone marrow are not well understood.Using computational flow cytometry,we observed increased neutrophils in the lungs of patients and mice with PH.Moreover,we found elevated levels of IL-6 in the blood and lungs of patients and mice with PH.We observed that transgenic mice overexpressing Il-6 in the lungs displayed elevated neutrophil egress from the bone marrow and exaggerated neutrophil recruitment to the lungs,resulting in exacerbated pulmonary vascular remodeling,and dysfunctional hemodynamics.Mechanistically,we found that IL-6-induced neutrophil egress from the bone marrow was dependent on interferon regulatory factor 4(IRF-4)-mediated CX3CR1 expression in neutrophils.Consequently,Cx3cr1 genetic deficiency in hematopoietic cells in Il-6-transgenic mice significantly reduced neutrophil egress from bone marrow and decreased neutrophil counts in the lungs,thus ameliorating pulmonary remodeling and hemodynamics.In summary,these findings define a novel mechanism of IL-6-induced neutrophil egress from the bone marrow and reveal a new therapeutic target to curtail neutrophil-mediated inflammation in pulmonary vascular disease. | Jonathan Florentin Jingsi Zhao Yi-Yin Tai Sathish Babu Vasamsetti Scott P.O’Neil Rahul Kumar Anagha Arunkumar Annie Watson John Sembrat Grant C.Bullock Linda Sanders Biruk Kassa Mauricio Rojas Brian B.Graham Stephen Y.Chan Partha Dutta | 2021 | Cellular & Molecular Immunology2021，18，2： | 3 |
| 8 | Predictors of outcome following hip fracture. Admission time predicts length of stay and in-hospital mortality显示文摘 | John E Clague Elaine Craddock Glynn Andrew Michael A Horan Neil Pendleton | 2002 | Injury2002，，1： | 2 |
| 9 | Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart: A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association显示文摘 | Manuel D. Cerqueira Neil J. Weissman Vasken Dilsizian Alice K. Jacobs Sanjiv Kaul Warren K. Laskey Dudley J. Pennell John A. Rumberger Thomas Ryan Mario S. Verani | 2002 | Circulation: Journal of the American Heart Association2002，，： | 2 |
| 10 | Effect of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide concentrations on the mechanical and biological characteristics of cross-linked collagen fibres for tendon repair显示文摘Reconstituted type I collagen fibres have received considerable interest as tendon implant materials due to their chemical and structural similarity to the native tissue.Fibres produced through a semi-continuous extrusion process were cross-linked with different concentrations of the zerolength cross-linker 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide(EDC)in combination with N-hydroxysuccinimide(NHS).Tensile properties of the fibres were considered,along with imaging of both surface structure and fibrillar alignment.Resistance of the fibres to bacterial collagenase was investigated and fibre sections seeded with human tendon cells for biological characterization,including cell adhesion and proliferation.The work clearly demonstrated that whilst the concentration of EDC and NHS had no significant effect on the mechanics,a higher concentration was associated with higher collagenase resistance,but also provided a less attractive surface for cell adhesion and proliferation.A lower cross-linking concentration offered a more biocompatible material without reduction in mechanics and with a potentially more optimal degradability. | Zafar Ahmad Jennifer H.Shepherd David V.Shepherd Siddhartha Ghose Simon J.Kew Ruth E.Cameron Serena M.Best Roger A.Brooks John Wardale Neil Rushton | 2015 | Regenerative Biomaterials2015，2，2： | 2 |
| 11 | Seasonal Variation in Stroke in the Hunter Region, Australia: A 5-Year Hospital-Based Study, 1995-2000显示文摘 | Yang Wang Christopher R. Levi John R. Attia Catherine A. D’Este Neil Spratt Janet Fisher | 2003 | Stroke: Journal of the American Heart Association2003，，5： | 2 |
| 12 | Evaluation of microdiets versus live feeds on growth, survival and fatty acid composition of larval haddock ( Melanogrammus aeglefinus )显示文摘 | Tammy Blair John Castell Steven Neil Louis D’Abramo Chantal Cahu Paul Harmon Kehinde Ogunmoye | 2003 | Aquaculture2003，，1： | 2 |
| 13 | Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett’s esophagus?显示文摘 | Neil Gupta Sharad C. Mathur John A. Dumot Vikas Singh Srinivas Gaddam Sachin B. Wani Ajay Bansal Amit Rastogi John R. Goldblum Prateek Sharma | 2012 | Gastrointestinal Endoscopy2012，，： | 2 |
| 14 | Image-guided endoscopic evacuation of spontaneous intracerebral hemorrhage显示文摘 | Chad M. Miller Paul Vespa Jeffrey L. Saver Chelsea S. Kidwell Stanley T. Carmichael Jeffry Alger John Frazee Sid Starkman David Liebeskind Valeriy Nenov Robert Elashoff Neil Martin | 2008 | Surgical Neurology2008，，5： | 2 |
| 15 | Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image显示文摘 | Barbara C Silva William D Leslie Heinrich Resch Olivier Lamy Olga Lesnyak Neil Binkley Eugene V McCloskey John A Kanis John P Bilezikian | 2014 | J Bone Miner Res2014，，3： | 2 |
| 16 | Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma显示文摘 | Nourredine Himoudi Rebecca Wallace Kathryn Parsley Kimberly Gilmour Alpha-Umaru Barrie Karen Howe Rong Dong Neil Sebire Antony Michalski Adrian Thrasher John Anderson | 2012 | Clinical and Translational Oncology2012，，： | 2 |
| 17 | Practice Parameters for the Treatment of Perianal Abscess and Fistula-in-Ano ?(Revised)显示文摘 | Mark H. Whiteford M.D. John Kilkenny M.D. Neil Hyman M.D. W. Donald Buie M.D. Jeffrey Cohen M.D. Charles Orsay M.D. Gary Dunn M.D. W. Brian Perry M.D. C. Neal Ellis M.D. Jan Rakinic M.D. Sharon Gregorcyk M.D. Paul Shellito M.D. Richard Nelson M.D. Joe J. | 2005 | Diseases of the Colon & Rectum2005，，7： | 2 |
| 18 | 2004英国高血压学会高血压治疗指南(BHS-IV):概要显示文摘在高血压领域,不断出现的新证据已日益受到关注。例如:血压可作为心血管疾病的一个危险因素;改进生活方式对于预防和治疗高血压的重要意义;不同类型药物的有效性和安全性;高危高血压患者包括糖尿病患者的治疗;心血管疾病总体危险性评估的重要性以及使用他汀类药物所获得的额外益处。 | Bryan Williams Neil R Poulter Peter S Sever Morris J Brown Mark Davis Gordon T McInnes John F Potter 邱洪 | 2004 | 英国医学杂志中文版2004，7，5： | 2 |
| 19 | Protecting the delivery of heart failure: Regenerative Medicine/Stem Cell Therapeutics:Potential protections afforded by the Department of Health and Human Services and Health Resources Service Administration’s Bureau of Special Programs显示文摘Advances in stem cell science and potential clinical applications have brought clinical medicine closer to the actualization of Regenerative Medicine—an extension of transplantation of organs and cells and implantation of bioprosthetics and biodevices. The goal of such therapeutics will be intervention prior to onset of severe individual disability, enhance organ function and enhance patient performance status without incurring the economic impacts of standard organ transplantation. Regenerative Medicine is already demonstrating proof of principle or efficacy in restora- tion of myocardial contractility, joint mobility and function, immune competence, pulmonary function, immunologic self- tolerance, motor function and normal hemoglobin production with the next targets—diabetes mellitus (type I and type II), neurologic injury, hepatic dysfunction preparing to enter trials. Expenditures on health care needs of an aging U.S. citizenry approximate 20-25% ($3 trillion) of U.S. GDP currently and may to grow to 40% of U.S. GDP by 2025. As the potential of Regenerative Medicine is clinically realized, the societal impact and economic benefits will be disproportionately magnified in the economies of industrialized nations. The experi- ence of the Department of Health and Human Services (HHS), United Network for Organ Sharing (UNOS), the National Bone Marrow Donor Registry (NBMDR), and the National Vaccine Injury Compensation Programs (NVICP) can help ensure that as Regenerative Medicine strives to achieve clinical benefits while avoiding decimation of therapeutic options by product liability and medical malpractice concerns—concerns that crippled the U.S. vaccine manufacturing industry until the creation of the NVICP. The first 50 years of organ/cell/tissue transplantation demonstrates that clinical reality of allogeneic and autologous transplantation can antedate complete understanding of the basic science underlying successful transplantation. Product liability and medical malpractice liability have not impeded the development and growth of organ/cell/tissue transplanta- tion despite increased risks of infection, malignancy and cardiovascular disease in transplant recipients. Currently, human transplantation is only performed using FDA/CBER-approved, non-embryonic stem cells from peripheral blood, bone marrow or umbilical cord blood. Federal legislation passed in 2005 (HR2520 and S1317: The Bone Marrow and Cord Blood Cell Transplantation Program) authorizes the Secretary of Health and Human Services acting through the Director of HRSA to ensure uniform stem cell units distribution and outcomes monitoring via the federally-designated C.W. Bill Young Cell Transplant Program. Historically in the U.S., human biological therapies (vaccines, organ transplant and stem cell transplant) have re- quired federal protections to ensure continued distribution, fair access and avoidance of inhibitory product liability via protections afforded under the “stewardship” of the Secretary of Health and Human Services. The National Childhood Vaccine Injury Act of 1986 established the NVICP to equitably and expeditiously compensate individuals, or families of individuals, who have been declared injured by vaccines, thereby stabilizing a once imperiled vaccine supply by substan-tially reducing the threat of liability for vaccine companies, physicians, and other health care professionals who administer vaccines. Vaccines were the first biologics administered to U.S. citizens en masse and presage stem cell therapeutics (which may similarly be administered to millions) will similarly necessitate that a Stem Cell Injury Compensation Program (SCICP) will also need to be in place to demonstrate an intention to do good, an understanding that industry may do well, but that the health care consumer has a right of protection—all recognized from the outset. The Federal Tort Claims Act (FTCA) addresses liability claims via the Executive, Judicial and Legislative branches of Government, providing an um- brella of liability protection to other participants in the stem cell unit “chain of custody” under the FTCA—similar to the protection from product liability seen in organ and stem cell transplantation for the past 40-50 years. Efficacious development of regenerative medicine capabilities will mandate controlled access must first be provided for individuals with life-threatening diseases without therapeutic options or unable to benefit from or receive proven therapeutic options (ALS, cardiomyopathy and deemed not a candidate for heart transplantation, IDDM with hypoglyce- mic unawareness and no allogeneic source of traditional islet cell replacement available via HRSA) and mandates the prompt adoption of business and legal principles to ensure that the fate of the vaccine manufacturing industry does not become the fate of the stem cell therapeutics industry. If legal and regulatory concerns consume an increasing percentage of health care dollars that could be focused upon innovation, the Regenerative Medicine model will have not realized its full potential. The Diabetes Transplantation/Regenerative Medicine Model is the first organ to cell transplant model outside of oncology to demonstrate the regenerative medicine paradigm. Since all human tissues can be already recapitulated by human stem cells and key patent holders already exist, outlet or distribution of “more-than-minimally-manipulated stem cell units” as an IND approved under FDA/CBER guidelines can be accomplished via the current HHS/HRSA/Dept of Trans- plant methodology. As cardiovascular stem cell researchers develop human therapeutics utilizing more-than-minimally- manipulated stem cell products, they could be afforded protections from product liability historically enjoyed by the transplant community. Extending the Diabetes Transplant/Regenerative Medicine Model to the more than 5 million Americans with chronic heart failure, cell-based therapies to regenerate myocardial contractility could fill an existing void and be delivered in conjunction with and consistent with existing distribution of organs and tissues via HRSA/Department of Transplantation. | Gary S Friedman John S. Tomicki Neil Cohen Robert Marshal Philip Lowry Jeffrey Warsh | 2006 | Journal of Geriatric Cardiology2006，3，3： | 2 |
| 20 | Electroacupuncture for Control of Myeloablative Chemotherapy-Induced Emesis显示文摘 | Joannie Shen Neil Wenger John Glaspy | 2000 | JAMA2000，284，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员